To test whether IL-33 influences cell survival via p38 signaling in primary samples, we treated BM and PB cells from AML patients with IL-33 or SB alone, or in combination in culture for 72 h and measured apoptosis and cell cycle status. This evidence concerns the gene IL33 and acute myeloid leukemia.